Factor IX Gene Analysis In 70 Unrelated Patients with Haemophilia B: Description of 13 New Mutations

Summary

Seventy unrelated patients suffering from haemophilia B have been screened for determining the molecular defect and for evaluating the spectrum of factor IX mutations in the Rhône Alpes region in France. Most patients were characterized with respect to factor IX antigen and factor IX coagulant activity. We have used denaturing gradient gel electrophoresis to obtain a full scanning of the whole coding, promoter, and exon flanking sequences of the factor IX gene. This technique enabled us to determine the molecular defect in 68 out of 70 families (97%), and the mutation was further identified in the two last patients with a direct sequencing of the gene. A total of 2 complete gene deletions in patients with antifactor IX inhibitor, 6 small insertions/ deletions and 62 point mutations were found. Two of these nucleotide substitutions (Arg145His and Ala233Thr) were detected in 21 patients (30%) suggesting the existence of a local founder effect. Thirteen mutations were previously undescribed, including 7 missense mutations. The detection of mutations in patients affected with haemophilia B may shed some light in the structure-function relationship of factor IX molecule within the coagulation system.

Keywords

Haemophilia B - factor IX gene - mutations

^# Both authors contributed at the same level to the paper

• References

• 1 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-50.
• 2 Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions-eighth edition. Nucleic Acids Res 1998; 26: 265-8.
• 3 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one stage clotting test. J Lab Clin Med 1953; 41: 637-41.
• 4 Sambrook J, Fritsch EF, Maniatis T. In: Molecular cloning. Cold Spring Harbour Laboratory press; New York USA: 1989. vol. 2 9.16-9.19.
• 5 Lerman LS, Silverstein K. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 1987; 155: 482-500.
• 6 Ghanem N, Costes B, Martin J, Vidaud M, Rothschild C, Foyer Gazengel C, Goossens M. Twenty-four novel hemophilia B mutations revealed by rapid scanning of the whole factor IX gene in a French population sample. Eur J Hum Genet 1993; 1: 144-55.
• 7 Top B. A simple method to attach a universal 50-bp GC-clamp to PCR fragments used for mutation analysis by DGGE. PCR Methods and Appl 1992; 2: 83-5.
• 8 Myers RM, Fischer SG, Lerman LS, Maniatis T. Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucleic Acids Res 1985; 13: 3131-45.
• 9 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
• 10 Bowen DJ, Thomas P, Webb CE, Bignell P, Peake IR, Bloom AL. Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. Br J Haematol 1991; 77: 559-60.
• 11 Graham JB, Kunkel GR, Tennyson GS, Lord ST, Fowlkes DM. The Malmo polymorphism of factor IX: establishing the genotypes by rapid analysis of DNA. Blood 1989; 73: 2104-7.
• 12 Winship PR, Rees DJ, Alkan M. Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of haemophilia B carriers [see comments]. Lancet 1989; 1: 631-4.
• 13 Myers R, Maniatis T, Lerman LS. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol 1987; 155: 501-27.
• 14 Macek Jr. M, Mercier B, Mackova A, Miller PW, Hamosh A, Ferec C, Cutting GR. Sensitivity of the denaturing gradient gel electrophoresis technique in detection of known mutations and novel Asian mutations in the CFTR gene. Hum Mutat 1997; 9: 136-47.
• 15 Tartary M, Vidaud D, Piao Y, Costa JM, Bahnak BR, Fressinaud E, Congard B, Laurian Y, Meyer D, Lavergne JM. et al. Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. Br J Haematol 1993; 84: 662-9.
• 16 Crossley M, Winship PR, Austen DE, Rizza CR, Brownlee GG. A less severe form of Haemophilia B Leyden. Nucleic Acids Res 1990; 18: 4633.
• 17 Hirosawa S, Fahner JB, Salier JP, Wu CT, Lovrien EW, Kurachi K. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden. Proc Natl Acad Sci USA 1990; 87: 4421-5.
• 18 Morgan GE, Figueiredo MS, Winship PR, Baker R, Bolton Maggs PH, Brownlee GG. The high frequency of the -6G(A factor IX promoter mutation is the result both of a founder effect and recurrent mutation at a CpG dinucleotide. Br J Haematol 1995; 89: 672-4.
• 19 Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 1: 49-52.
• 20 Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Petrini P, Lusher JM. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
• 21 Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
• 22 Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHC-DO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
• 23 Green PM, Montandon AJ, Bentley DR, Ljung R, Nilsson IM, Giannelli F. The incidence and distribution of CpG → TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res 1990; 18: 3227-31.
• 24 Saad S, Rowley G, Tagliavacca L, Green PM, Giannelli F. UK haemophilia centres. First report on UK database of haemophilia B mutations and pedigrees. Thromb Haemost 1994; 71: 563-70.
• 25 Haldane JBS. The mutation rate of the gene for haemophilia and its segregation ratios in males and females. Ann Eugenet (Lond) 13: 262-71.
• 26 Knobloch O, Zoll B, Zerres K, Brackmann HH, Olek K, Ludwig M. Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Investigation of the German haemophilia B population and review of de novo mutations. Hum Genet 1993; 92: 40-8.
• 27 Sunnerhagen M, Forsén S, Hoffrén AM, Drakenberg T, Teleman O, Stenflo J. Structure of the calcium free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol 1995; 2: 504-9.
• 28 Hughes PE, Handford PA, Austen DE, Brownlee GG. Protein engineering of the hydrophobic domain of human factor IX. Protein Eng 1994; 7: 1121-7.
• 29 Sunnerhagen M, Olah GA, Stenflo J, Forsén S, Drakenberg T, Trewhella J. The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca⁺⁺ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. Biochemistry 1996; 35 (36) 11547-59.
• 30 Kelly CR, Dickinson CD, Ruf W. Ca²⁺ binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function. J Biol Chem 1997; 272: 17467-72.
• 31 Christophe OD, Lenting PJ, Kolkman JA, Brownlee GG, Mertens K. Blood coagulation factor IX residues Glu⁷⁸ and Arg⁹⁴ provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. J Biol Chem 1998; 273: 222-7.
• 32 Weinmann AF, Murphy ME, Thompson AR. Consequences of factor IX mutations in 26 families with haemophilia B. Br J Haematol 1998; 100: 58-61.
• 33 Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998; 4: 285-90.